RVMD - REVOLUTION Medicines Inc Stock Price, Fair Value and News

35.59USD-0.67 (-1.85%)Market Closed

Market Summary

USD35.59-0.67

Market Closed

-1.85%

RVMD Alerts

1 major insider sales recently.

RVMD Stock Price

View Fullscreen

RVMD RSI Chart

RVMD Valuation

Market Cap

6.0B

Price/Earnings (Trailing)

-13.68

Price/Sales (Trailing)

515.69

EV/EBITDA

-12.13

Price/Free Cashflow

-16.67

RVMD Price/Sales (Trailing)

RVMD Profitability

EBT Margin

-3798.71%

Return on Equity

-23.89%

Return on Assets

-21.17%

Free Cashflow Yield

-6%

RVMD Fundamentals

RVMD Revenue

Revenue (TTM)

11.6M

Rev. Growth (Yr)

-95.16%

Rev. Growth (Qtr)

-100%

RVMD Earnings

Earnings (TTM)

-436.4M

Earnings Growth (Yr)

-185.87%

Earnings Growth (Qtr)

-48.97%

Breaking Down RVMD Revenue

Last 7 days

0.0%

Last 30 days

17.5%

Last 90 days

31.5%

Trailing 12 Months

57.5%

How does RVMD drawdown profile look like?

RVMD Financial Health

Current Ratio

13.06

RVMD Investor Care

Shares Dilution (1Y)

82.00%

Diluted EPS (TTM)

-3.85

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	34.8M	29.5M	26.2M	11.6M
2022	26.8M	27.3M	29.5M	35.4M
2021	41.6M	40.2M	28.7M	29.4M
2020	48.4M	46.2M	46.3M	43.0M
2019	27.6M	35.1M	42.6M	50.0M
2018	0	0	0	20.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of REVOLUTION Medicines Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 10, 2024	patel sushil	acquired	36,204	16.8	2,155	-
Apr 10, 2024	patel sushil	sold	-79,735	37.00	-2,155	-
Apr 10, 2024	goldsmith mark a	sold	-266,122	35.4829	-7,500	see remarks
Apr 10, 2024	goldsmith mark a	sold	-353,346	35.3345	-10,000	see remarks
Mar 27, 2024	cislini jeff	sold	-46,481	30.9873	-1,500	general counsel
Mar 18, 2024	kelsey stephen michael	sold	-67,051	31.5832	-2,123	see remarks
Mar 18, 2024	cislini jeff	sold	-39,542	31.5832	-1,252	general counsel
Mar 18, 2024	horn margaret a	sold	-92,033	31.5832	-2,914	chief operating officer
Mar 18, 2024	goldsmith mark a	sold	-182,804	31.5832	-5,788	see remarks
Mar 18, 2024	anders jack	sold	-39,826	31.5832	-1,261	chief financial officer

Which funds bought or sold RVMD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 22, 2024	MetLife Investment Management, LLC	added	41.03	682,586	2,162,390	0.02%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	reduced	-13.71	-25,231	808,812	-%
Apr 18, 2024	SJS Investment Consulting Inc.	reduced	-25.00	-18.00	97.00	-%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	new	-	103,716	103,716	-%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	reduced	-21.02	-36,399	287,169	0.01%
Apr 12, 2024	AdvisorNet Financial, Inc	sold off	-100	-115	-	-%
Apr 12, 2024	DLK Investment Management, LLC	unchanged	-	-11,357	14,053	0.01%
Apr 12, 2024	ARMSTRONG ADVISORY GROUP, INC	unchanged	-	-	8,719	-%
Apr 11, 2024	Fortitude Family Office, LLC	unchanged	-	898	8,154	-%
Apr 10, 2024	Wedmont Private Capital	unchanged	-	181,536	1,636,300	0.12%

Are Funds Buying or Selling RVMD?

Are funds buying RVMD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RVMD

No. of Funds

RVMD Alerts

1 major insider sales recently.

Unveiling REVOLUTION Medicines Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	biotechnology value fund l p	1.9%	3,079,232	SC 13G/A
Feb 14, 2024	ecor1 capital, llc	0.1%	132,579	SC 13G/A
Feb 13, 2024	bb biotech ag	3.1%	5,046,700	SC 13G/A
Feb 13, 2024	vanguard group inc	8.93%	14,634,391	SC 13G/A
Feb 12, 2024	farallon capital partners, l.p.	0.2%	329,602	SC 13G/A
Feb 09, 2024	column group iii, lp	0%	0	SC 13G/A
Feb 08, 2024	wellington management group llp	9.09%	14,882,086	SC 13G/A
Jan 26, 2024	blackrock inc.	7.9%	12,954,314	SC 13G/A
Nov 09, 2023	farallon capital partners, l.p.	0.3%	291,600	SC 13G
Nov 09, 2023	wellington management group llp	12.99%	14,219,430	SC 13G/A

Recent SEC filings of REVOLUTION Medicines Inc

View All Filings

Date Filed	Form Type	Document
Apr 12, 2024	4	Insider Trading
Apr 12, 2024	4	Insider Trading
Apr 10, 2024	144	Notice of Insider Sale Intent
Apr 10, 2024	144	Notice of Insider Sale Intent
Apr 10, 2024	144	Notice of Insider Sale Intent
Apr 10, 2024	144	Notice of Insider Sale Intent
Mar 29, 2024	3	Insider Trading
Mar 28, 2024	4	Insider Trading
Mar 27, 2024	144	Notice of Insider Sale Intent
Mar 20, 2024	4	Insider Trading

Peers (Alternatives to REVOLUTION Medicines Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	2.33%	-21.90%	-8.74	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.30%	-28.67%	-41.79	10.06	76.23%	61.08%
BMRN	17.4B	2.4B	8.14%	-4.26%	103.61	7.18	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.4	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.5B	-	-13.93%	67.39%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-9.40%	-0.33%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.74%	-16.88%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.36%	-10.84%	24.31	4.36	85.90%	-14.05%
NVAX	587.8M	983.7M	-10.64%	-48.02%	-1.08	0.6	-50.36%	17.16%
CRBP	396.0M	881.7K	8.01%	271.09%	-8.88	466.16	-77.61%	-5.33%
INO	242.4M	4.9M	-10.76%	0.48%	-1.79	49.8	-54.97%	51.71%
IBIO	6.7M	2.1M	76.15%	62.71%	-0.25	2.14	-13.45%	66.37%

REVOLUTION Medicines Inc News

Latest updates

REVOLUTION Medicines Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-	742,000	-	3,824,000	7,014,000	15,330,000	3,356,000	9,116,000	7,578,000	9,460,000	1,101,000	8,698,000	10,131,000	8,751,000	12,661,000	10,025,000	11,546,000	12,088,000	12,506,000	12,281,000	13,166,000	-
Operating Expenses	46.6%	180,725,000	123,248,000	112,621,000	82,171,000	77,037,500	79,889,000	71,205,000	65,527,000	62,373,000	54,264,000	53,233,000	47,528,000	42,831,000	40,212,000	38,009,000	32,628,000	31,652,000	26,065,000	22,842,000	23,602,000	-
S&GA Expenses	107.9%	32,244,000	15,513,000	14,640,000	13,224,000	10,910,500	10,434,000	10,204,000	9,037,000	8,692,000	7,791,000	7,297,000	6,670,000	5,825,000	5,341,000	5,091,000	5,171,000	4,162,000	3,103,000	2,725,000	2,416,000	-
R&D Expenses	37.8%	148,481,000	107,735,000	97,981,000	68,947,000	66,127,000	69,455,000	61,001,000	56,490,000	53,681,000	46,473,000	45,936,000	40,858,000	37,006,000	34,871,000	32,918,000	27,457,000	27,490,000	22,962,000	20,117,000	21,186,000	-
EBITDA Margin	-197.3%	-37.55	-12.63	-9.89	-7.33	-6.93	-8.18	-8.11	-7.61	-6.26	-5.76	-3.47	-2.95	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	12,000	14,000	17,000	19,000	21,000	-	-	-	-	-
Income Taxes	108.9%	343,000	-3,867,000	-	-	-123,000	-297,000	-	-	-	-	-	-	362,000	-	-58,000	-675,000	-	-	-	-	-
Earnings Before Taxes	-43.5%	-161,194,000	-112,301,000	-98,298,000	-68,098,000	-56,630,000	-73,626,000	-61,222,000	-57,647,000	-52,676,000	-52,940,000	-44,299,000	-37,176,000	-33,842,000	-27,221,000	-27,273,000	-20,194,000	-18,969,000	-12,818,000	-10,119,000	-10,131,000	-
EBT Margin	-196.4%	-37.99	-12.81	-10.05	-7.46	-7.04	-8.31	-8.24	-7.73	-6.37	-5.87	-3.54	-3.02	-	-	-	-	-	-	-	-	-
Net Income	-49.0%	-161,537,000	-108,434,000	-98,298,000	-68,098,000	-56,507,000	-73,329,000	-61,222,000	-57,647,000	-52,676,000	-52,940,000	-44,299,000	-37,176,000	-34,204,000	-27,221,000	-27,215,000	-19,519,000	-14,596,000	-12,818,000	-10,119,000	-10,131,000	-
Net Income Margin	-197.6%	-37.68	-12.66	-10.03	-7.44	-7.03	-8.30	-8.24	-7.73	-6.37	-5.88	-3.55	-3.03	-	-	-	-	-	-	-	-	-
Free Cashflow	-19.3%	-122,880,000	-103,032,000	-68,240,000	-64,149,000	-64,664,000	-55,262,000	-58,242,000	-57,049,000	-40,448,000	-37,042,000	-35,393,000	-40,825,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																	(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Assets	109.5%	2,062	984	1,074	1,073	812	826	633	683	738	735	774	812	567	595	454	454	221
Current Assets	127.9%	1,879	824	922	923	660	675	483	534	590	624	661	697	454	483	340	362	134
Cash Equivalents	94.2%	696	358	380	427	161	179	106	98.00	108	129	196	352	104	65.00	24.00	183	17.00
Net PPE	12.7%	23.00	20.00	20.00	19.00	19.00	18.00	16.00	13.00	12.00	10.00	11.00	11.00	9.00	7.00	7.00	7.00	7.00
Goodwill	0%	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00
Liabilities	60.5%	236	147	143	121	127	144	134	132	135	97.00	89.00	89.00	93.00	90.00	93.00	69.00	68.00
Current Liabilities	68.2%	144	86.00	78.00	55.00	62.00	73.00	64.00	57.00	60.00	52.00	46.00	44.00	47.00	42.00	44.00	42.00	43.00
Shareholder's Equity	118.1%	1,826	837	931	952	685	681	499	551	603	638	685	723	475	505	360	385	-
Retained Earnings	-16.5%	-1,137	-976	-867	-769	-701	-644	-571	-510	-452	-400	-347	-302	-265	-231	-204	-176	-157
Additional Paid-In Capital	63.3%	2,963	1,814	1,800	1,722	1,388	1,329	1,072	1,063	1,056	1,038	1,032	1,025	740	736	564	562	5.00
Shares Outstanding	50.5%	165	109	109	106	90.00	85.00	74.00	74.00	73.00	72.00	73.00	70.00	-	-	-	-	-
Float	-	-	-	2,757	-	-	-	1,231	-	-	-	1,956	-	-	-	1,107	-	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-20.0%	-120	-100	-67.12	-62.39	-61.79	-51.74	-55.72	-55.16	-39.26	-36.59	-34.08	-37.25	-25.03	-27.02	-19.99	-28.02	-11.65	-13.86	-11.50	-12.60	-
Share Based Compensation	86.1%	25.00	14.00	13.00	10.00	8.00	8.00	8.00	7.00	6.00	6.00	5.00	3.00	3.00	3.00	2.00	2.00	1.00	1.00	1.00	0.00	-
Cashflow From Investing	-591.8%	-380	77.00	-43.54	4.00	-7.10	-123	62.00	44.00	9.00	-30.18	-122	2.00	63.00	-100	-136	-59.72	8.00	-59.80	-55.95	6.00	-
Cashflow From Financing	82922.2%	839	1.00	65.00	324	51.00	248	1.00	0.00	11.00	0.00	1.00	282	1.00	169	-1.34	254	-1.53	10.00	90.00	0.00	-

RVMD Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Total revenue	$ 11,580	$ 35,380	$ 29,390
Revenue, Product and Service [Extensible Enumeration]	Collaboration Revenue Member	Collaboration Revenue Member	Collaboration Revenue Member
Operating expenses:
Research and development	$ 423,144	$ 253,073	$ 186,948
General and administrative	75,621	40,586	30,450
Total operating expenses	498,765	293,659	217,398
Loss from operations	(487,185)	(258,279)	(188,008)
Other income (expense), net:
Interest income	47,482	9,154	929
Interest and other expense	(303)	0	(12)
Change in fair value of warrant liability and contingent earn-out shares	115	0	0
Total other income, net	47,294	9,154	917
Loss before income taxes	(439,891)	(249,125)	(187,091)
Benefit from income taxes	3,524	420	0
Net loss	$ (436,367)	$ (248,705)	$ (187,091)
Net loss per share attributable to common stockholders, basic	$ (3.86)	$ (3.08)	$ (2.57)
Net loss per share attributable to common stockholders, diluted	$ (3.86)	$ (3.08)	$ (2.57)
Weighted-average shares used to compute net loss per share attributable to common stockholders, basic	113,149,869	80,626,525	72,806,079
Weighted-average shares used to compute net loss per share attributable to common stockholders, diluted	113,149,869	80,626,525	72,806,079
Comprehensive loss:
Net Income (Loss)	$ (436,367)	$ (248,705)	$ (187,091)
Other comprehensive income (loss):
Unrealized gain (loss) on investments, net	2,324	(1,404)	(492)
Comprehensive loss	$ (434,043)	$ (250,109)	$ (187,583)

RVMD Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 696,148	$ 161,412
Marketable securities	1,156,807	483,531
Account receivable	1,254	4,673
Prepaid expenses and other current assets	25,072	10,569
Total current assets	1,879,281	660,185
Property and equipment, net	22,865	18,659
Operating lease right-of-use asset	77,149	55,077
Intangible assets, net	57,739	58,807
Goodwill	14,608	14,608
Restricted cash	3,031	1,737
Other noncurrent assets	7,032	2,857
Total assets	2,061,705	811,930
Current liabilities:
Accounts payable	61,788	21,306
Accrued expenses and other current liabilities	74,694	29,446
Operating lease liability, current	7,369	6,773
Deferred revenue, current	0	4,459
Total current liabilities	143,851	61,984
Deferred tax liability	3,115	7,025
Operating lease liability, noncurrent	80,575	57,432
Warrant liability	6,512	0
Other noncurrent liabilities	1,458	301
Total liabilities	235,511	126,742
Commitments and contingencies (Note 8)
Stockholders' equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at December 31, 2023 and December 31, 2022, respectively; none issued and outstanding at December 31, 2023 and December 31, 2022, respectively	0	0
Common stock, $0.0001 par value; 300,000,000 shares authorized as of December 31, 2023 and December 31, 2022, respectively; 170,234,594 and 90,411,912 shares issued as of December 31, 2023 and December 31, 2022; 164,674,594 and 90,411,912 shares outstanding as of December 31, 2023 and December 31, 2022, respectively	16	9
Additional paid-in capital	2,963,342	1,388,300
Accumulated other comprehensive income (loss)	544	(1,780)
Accumulated deficit	(1,137,708)	(701,341)
Total stockholders' equity	1,826,194	685,188
Total liabilities and stockholders' equity	$ 2,061,705	$ 811,930

About REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a tri-complex inhibitor of KRASG12C(ON) and KRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

CEO	Dr. Mark A. Goldsmith Ph.D.
WEBSITE	revmed.com
INDUSTRY	Biotechnology
EMPLOYEES	292

REVOLUTION Medicines Inc Frequently Asked Questions

What is the ticker symbol for REVOLUTION Medicines Inc? What does RVMD stand for in stocks?

RVMD is the stock ticker symbol of REVOLUTION Medicines Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of REVOLUTION Medicines Inc (RVMD)?

As of Tue Apr 23 2024, market cap of REVOLUTION Medicines Inc is 5.97 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RVMD stock?

You can check RVMD's fair value in chart for subscribers.

What is the fair value of RVMD stock?

You can check RVMD's fair value in chart for subscribers. The fair value of REVOLUTION Medicines Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of REVOLUTION Medicines Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RVMD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is REVOLUTION Medicines Inc a good stock to buy?

The fair value guage provides a quick view whether RVMD is over valued or under valued. Whether REVOLUTION Medicines Inc is cheap or expensive depends on the assumptions which impact REVOLUTION Medicines Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RVMD.

What is REVOLUTION Medicines Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, RVMD's PE ratio (Price to Earnings) is -13.68 and Price to Sales (PS) ratio is 515.69. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RVMD PE ratio will change depending on the future growth rate expectations of investors.